Dispelling Wind Tongluozhitong Capsule In The Treatment Of Migraine (Chill Clip Stasis Type) Clinical Study

Purpose: In this experiment, the clinical trials use of internationally recognizeddiagnostic criteria, and evaluation standard, placebo-controlled evaluation of the Shufengthrough the network to the treatment of migraine pain relief capsules (cold folder StasisSyndrome) the effectiveness of.Method: Reference to the International Headache Classification of Diseases, publishedin January2004, in the second edition of the migraine diagnostic criteria (with aura, migrainewithout aura, migraine),traditional Chinese Drug treatment of migraine,"Traditional ChineseDrug Guidelines for clinical research clinical research guidelines (2002version) andtraditional Chinese medicine syndrome authentication diagnostics", Zhao Jinduo editor(1987),screening a total of48patients were enrolled using computer randomization allocatedpatients according to the ratio of1:1,treatment group and24(Shufeng Tongluo pain Capsules)placebo group and24(placebo-controlled);Whether the differences observed two groups ofchildren patients and statistically meaningless.Result: Clinical efficacy of headache extent (vas) score, vas score in treatment groups:before and after the treatment group compared with vas score before and after treatment weresignificantly different, statistically meaningful, p0.05; Placebo group: before and aftertreatment vas score, no difference was not statistically significant, p>0.05; After treatmentvas score were significantly different, p <0.05, indicating that the treatment group wassignificantly superior to placebo.Through clinical symptom efficacy analysis, treatment groupwere more rate was62.5%,87.5%,0.04%of the placebo group were more rate, the totalefficiency of16.6%in both groups and the difference was significant (p <0.05), clinicalTCMsymptoms were significantly better than the placebo group.Conclusion: The results of clinical studies show that, Shufeng Tongluo pain reliefcapsules for migraine (cold folder Stasis Syndrome) is effective and significantly superior toplacebo to relieve headaches extent, no adverse reactions, clinical use and development value.